1-5 of 5
Weiguo Su
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Long-Term Sovleplenib Treatment of Adults with Primary Immune Thrombocytopenia in China

Yu Hu, Renchi Yang, Xiaofan Liu, Heng Mei, Hu Zhou, Shujie Wang, Ruibin Huang, Yi Wang, Xin Du, Jing Sun, Zeping Zhou, Zhenyu Yan, Wenming Chen, Wei Wang, Qingchi Liu, Qingshu Zeng, Yuping Gong, Jie Yin, Xuliang Shen, Baodong Ye, Yun Chen, Yajing Xu, Huiping Sun, Yunfeng Cheng, Zhuogang Liu, Chunling Wang, Guolin Yuan, Xiaohui Zhang, Xin Li, Peng Cheng, Xinhong Guo, Zhongxing Jiang, Feng'e Yang, Linhua Yang, Chengwei Luo Luo, Taiwu Xiao, Hongyan Yin, Xiaojun Guo, Xian Luo, Songhua Fan, Michael M. Shi, Weiguo Su
Journal: Blood
Blood (2024) 144 (Supplement 1): 2558.
https://doi.org/10.1182/blood-2024-204447
Published: 2024
Journal Articles

Safety, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Adult Patients with Primary Immune Thrombocytopenia: A Randomized, Double-Blind and Placebo-Controlled Phase 1b Study

Renchi Yang, Hu Zhou, Yu Hu, Jie Yin, Junmin Li, Wenming Chen, Ruibin Huang, Yuping Gong, Chenwei Luo, Liu Xiaofan, Heng Mei, Bingjie Ding, Chengyuan Gu, Huiping Sun, Leng Yun, Dexiang Ji, Yan Li, Haiyan Shi, Hongyan Yin, Songhua Fan, Jian Wang, Weiguo Su
Journal: Blood
Blood (2021) 138 (Supplement 1): 16.
https://doi.org/10.1182/blood-2021-149895
Published: 2021
Journal Articles

Results from a Phase 1 Dose Escalation Study of HMPL-689, a Selective Oral Phosphoinositide 3-Kinase-Delta Inhibitor, in Chinese Patients with Relapsed/Refractory (R/R) Lymphomas

Junning Cao, Zhiming Li, MD PhD, Jianfeng Zhou, MD PhD, Dongmei Ji, MD PhD, Weina Shen, PhD, Peng Sun, MD, Yu Wang, MD, Dengju Li, MD, Zhenya Hong, MDPhD, Gaoxiang Wang, MDPhD, Xianlin Duan, MD, Chen Yu, MD, Yu Cai, PhD, Weiguo Su, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 38.
https://doi.org/10.1182/blood-2020-136013
Published: 2020
Journal Articles

Preliminary Results from a Phase 1 Study of HMPL-523, a Highly Selective Syk Inhibitor, in Chinese Patients with Mature B-Cell Lymphomas

Jun Zhu, MD PhD, Junning Cao, MD, Lugui Qiu, MD PhD, Junyuan Qi, MD, Yuqin Song, MD PhD, Meifeng Tu, MD PhD, Dongmei Ji, MD PhD, Weina Shen, MD, Mingyuan Sun, MD, Ye Hua, MD, Chen Yang, MD, Chen Yu, MD, Jian Wang, PhD, Guangxiu Dai, PhD, Weiguo Su, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5324.
https://doi.org/10.1182/blood-2018-99-111648
Published: 2018
Journal Articles

HMPL-523, a Novel SYK Inhibitor Showed Anti-Tumor Activities In Vitro and In Vivo

Na Yang, Wei Deng, Qiaoling Sun, Junqing Liang, Linfang Wang, Shiming Fan, Renxiang Tang, Ying Yu, Junen Sun, Feng Zhou, Guangxiu Dai, Weiguo Qing, Weiguo Su, Yongxin Ren
Journal: Blood
Blood (2016) 128 (22): 3970.
https://doi.org/10.1182/blood.V128.22.3970.3970
Published: 2016